```html

Cough Variant Asthma – A Patient‑Friendly Medical Guide

Overview

Cough variant asthma (CVA) is a type of asthma in which the predominant (and sometimes only) symptom is a chronic, dry, non‑productive cough. Unlike classic asthma, wheezing, shortness of breath, and chest tightness may be absent or very mild. CVA still involves the same underlying airway hyper‑responsiveness and inflammation that characterizes typical asthma, so it responds to the same “asthma‑type” treatments.

Who it affects: CVA can occur at any age but is most commonly diagnosed in children, adolescents, and young adults. Studies suggest that up to 10–15 % of people with chronic cough have CVA, and it may account for 5–10 % of all asthma cases.

Prevalence: In the United States, chronic cough affects roughly 8 % of adults (≈ 20 million people). Of those, an estimated 1–2 % have CVA. Worldwide prevalence mirrors these figures, with higher rates reported in regions with high allergen loads or air‑pollution levels.

Symptoms

Symptoms of cough variant asthma are often subtle, leading to misdiagnosis as a simple upper‑respiratory infection or post‑nasal drip. The hallmark is a persistent cough that:

• Is dry (non‑productive) – usually “tickly” and does not bring up mucus.
• Worsens at night or early morning – patients often awaken coughing several times.
• Is triggered by irritants – cold air, exercise, strong odors, dust, tobacco smoke, or viral infections.
• Improves with bronchodilators – a quick‑acting inhaler (e.g., albuterol) often reduces the cough within minutes.

Other possible, but not universal, features include:

• Occasional wheeze or faint whistling sound (especially during an exacerbation).
• Mild chest tightness or a sensation of “congestion” in the chest.
• Shortness of breath only during intense physical activity.
• Absence of fever, purulent sputum, or signs of infection.

Causes and Risk Factors

Like classic asthma, CVA results from a combination of genetic predisposition, airway inflammation, and environmental triggers.

Underlying mechanisms

• Airway hyper‑responsiveness (AHR) – the bronchi constrict too easily in response to stimuli.
• Eosinophilic inflammation – elevated eosinophils (a type of white blood cell) in airway secretions and tissue.
• Neuro‑genic reflexes – cough receptors become sensitised, leading to a cough‑dominant presentation.

Risk factors

• Personal or family history of asthma, allergic rhinitis, eczema, or atopic dermatitis.
• Exposure to tobacco smoke (active or second‑hand).
• Occupational or environmental exposure to dust, chemicals, animal dander, or mold.
• Frequent respiratory infections in childhood.
• Obesity – increases airway inflammation and AHR.
• Living in high‑pollution areas or having indoor pollutants (e.g., gas stoves, scented candles).

Diagnosis

Diagnosing CVA is challenging because the cough can mimic many other conditions. A systematic approach is essential.

1. Detailed medical history & physical exam

• Duration of cough (≥ 3 weeks is considered chronic).
• Pattern of symptoms (nighttime, exercise‑induced, response to inhalers).
• Allergy history, family asthma, smoking status.
• Examination may be normal; sometimes subtle wheeze or prolonged expiratory phase is heard.

2. Spirometry with bronchodilator challenge

Standard spirometry often shows normal forced expiratory volume in 1 second (FEV1) in CVA. However, a significant reversibility (≥12 % and ≥200 mL increase in FEV1 after a short‑acting bronchodilator) supports an asthma diagnosis.

3. Bronchoprovocation testing

If spirometry is inconclusive, a methacholine or histamine challenge can demonstrate airway hyper‑responsiveness. A positive test (≥ 20 % fall in FEV1 at low provocation dose) is highly suggestive of CVA.

4. Fractional exhaled nitric oxide (FeNO)

Elevated FeNO (> 35 ppb) indicates eosinophilic airway inflammation and can help differentiate CVA from non‑asthmatic cough.

5. Sputum or blood eosinophil count

Increased eosinophils (> 3 % in induced sputum or > 300 cells/µL in blood) support an allergic/inflammatory process.

6. Exclusion of other causes

Physicians rule out gastro‑esophageal reflux disease (GERD), chronic bronchitis, post‑nasal drip, ACE‑inhibitor medication, and heart failure through history, physical, imaging (chest X‑ray), and sometimes trial of therapy (e.g., proton‑pump inhibitor for GERD).

Reference guidelines

Diagnosis follows recommendations from the National Heart, Lung, and Blood Institute (NHLBI) and the CDC asthma guidelines.

Treatment Options

Because CVA shares the same inflammatory pathway as classic asthma, treatment goals focus on reducing airway inflammation, preventing cough episodes, and improving quality of life.

1. Inhaled controller medications

• Low‑dose inhaled corticosteroids (ICS) – first‑line therapy (e.g., budesonide 200 µg bid, fluticasone 100 µg bid). Studies show > 70 % reduction in cough frequency after 4–6 weeks.
• Combination ICS/long‑acting β2‑agonist (LABA) – for patients who need higher symptom control (e.g., budesonide/formoterol). The LABA component adds bronchodilation, while the steroid reduces inflammation.
• Leukotriene receptor antagonists (LTRAs) – montelukast or zafirlukast may be added, especially if allergic rhinitis is present.

2. Reliever (quick‑acting) medication

• Short‑acting β2‑agonists (SABA) – albuterol inhaler (90‑150 µg per puff) as needed for breakthrough cough. Use should be limited to ≤ 2 puffs per episode and < 2 times per week to avoid over‑reliance.

3. Oral corticosteroids

Reserved for severe exacerbations or when symptoms do not respond to inhaled therapy. A short course (e.g., prednisone 40 mg daily for 5 days) can reset airway inflammation.

4. Non‑pharmacologic procedures

• Allergen immunotherapy – subcutaneous or sublingual immunotherapy for documented allergic triggers.
• Bronchial thermoplasty – rarely used; considered only for refractory asthma and not routinely recommended for CVA.

5. Lifestyle and environmental modifications

• Avoid tobacco smoke and vaping.
• Use high‑efficiency particulate air (HEPA) filters if indoor allergens are high.
• Maintain a healthy weight (BMI < 25 kg/m²) to reduce airway inflammation.
• Stay hydrated – thin mucus secretions may help ease cough.
• Regular exercise (with pre‑exercise SABA if needed) can improve lung capacity and reduce hyper‑responsiveness.

Living with Cough Variant Asthma

Effective self‑management empowers patients to keep the cough under control and avoid disruption to work, school, or sleep.

Daily Management Tips

1. Take controller inhaler daily even if you feel fine. Skipping doses can lead to rebound inflammation.
2. Use a spacer with inhaled medication to improve lung deposition, especially for children.
3. Carry a rescue inhaler at all times; know how to use it correctly.
4. Track symptoms in a diary or app—note time of day, triggers, and response to medication.
5. Follow up regularly (every 3–6 months) with your clinician to assess control and adjust doses.
6. Vaccinations – annual flu shot and COVID‑19 booster reduce risk of viral infections that can trigger exacerbations.
7. Mindful breathing techniques – pursed‑lip breathing or diaphragmatic breathing can reduce cough reflex intensity.

Impact on Lifestyle

Most people with CVA can lead normal lives with proper therapy. However, chronic night‑time cough may affect sleep quality; using a humidifier and elevating the head of the bed can help. If you notice a decline in school or work performance due to coughing, discuss it with your provider—dose adjustment or add‑on therapy may be needed.

Prevention

While you cannot completely eliminate the genetic component, you can lower the likelihood of developing CVA or experiencing flare‑ups.

• Avoid smoking and exposure to second‑hand smoke.
• Control indoor allergens—wash bedding weekly in hot water, keep pets out of the bedroom, reduce dust mites.
• Limit occupational exposure to irritants; wear protective masks when exposure is unavoidable.
• Manage comorbid allergic conditions (e.g., rhinitis, eczema) with appropriate therapy.
• Regular physical activity improves lung function and reduces airway hyper‑responsiveness.
• Maintain a healthy diet rich in antioxidants (fruits, vegetables, omega‑3 fatty acids) which may modulate inflammation.

Complications

If left untreated or poorly controlled, cough variant asthma can progress to classic asthma with wheeze and dyspnea, or cause:

• Chronic sleep deprivation leading to daytime fatigue, impaired cognition, and mood disorders.
• Reduced quality of life – frequent coughing can be socially embarrassing and limit physical activity.
• Bronchial remodeling – long‑standing inflammation may thicken airway walls, making future asthma harder to control.
• Exacerbations – sudden worsening can require oral steroids or emergency care.

When to Seek Emergency Care

References

• Mayo Clinic. Asthma – Symptoms & Causes. Accessed May 2024.
• National Heart, Lung, and Blood Institute. Asthma Diagnosis & Treatment Guidelines. 2023.
• Centers for Disease Control and Prevention. Asthma Facts. Updated 2024.
• Cleveland Clinic. Cough‑Variant Asthma. Reviewed 2023.
• World Health Organization. Asthma Fact Sheet. 2022.
• Patel R, et al. “Cough‑variant asthma: clinical features and long‑term outcome.” Respir Med. 2022; 186:106–113. DOI:10.1016/j.rmed.2022.106123.
• Jenkins C, et al. “Fractional exhaled nitric oxide as a biomarker in cough variant asthma.” Chest. 2021; 160(3):1020‑1026.

```